Skip to main navigation Skip to search Skip to main content

Hyperbilirubinemia and retinopathy of prematurity: a retrospective cohort study

  • Silvia Gulden
  • , Gaia Cervellini
  • , Marta Colombo
  • , Maria Beatrice Marangoni
  • , Vittoria Taccani
  • , Nicola Pesenti
  • , Genny Raffaeli*
  • , Gabriella Araimo
  • , Silvia Osnaghi
  • , Monica Fumagalli
  • , Felipe Garrido
  • , Eduardo Villamor
  • , Giacomo Cavallaro
  • *Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Retinopathy of prematurity (ROP) is a vasoproliferative retinal disease in preterm infants. Oxidative stress plays a key role in the pathogenesis of ROP. Due to its antioxidant effects, bilirubin has been proposed to be protective against ROP. This study explored the association between hyperbilirubinemia and ROP. We analyzed a 10-year cohort from a neonatal intensive care unit in Milan, Italy, including 1606 infants born under 32 weeks and/or < 1500 g. Data from 1606 infants meeting specific inclusion criteria were reviewed. Eighty infants were excluded due to lack of data, 1526 were deemed eligible for analysis, and 1269 had hyperbilirubinemia requiring phototherapy. There was a higher incidence of ROP among infants with hyperbilirubinemia (13.8%) versus those without (7.8%, p<0.01). Infants with any ROP, non-severe or severe ROP, were exposed to hyperbilirubinemia for a significantly higher number of days compared with those without ROP. Each additional day of exposure increases the risk of developing any ROP by 5%, non-severe ROP by 4%, and severe ROP by 6%. However, this correlation was not observed in infants with gestational age less than 27 weeks and/or body weight less than 1000 g. Conclusion: Our data show that hyperbilirubinemia requiring phototherapy is associated with an increased risk of developing ROP. However, severe hyperbilirubinemia and ROP share many of their risk factors. Therefore, rather than being a risk factor itself, hyperbilirubinemia may be a surrogate for other risk factors for ROP. Clinical Trial Registration: NCT05806684. (Table presented.)

Original languageEnglish
Pages (from-to)3809-3818
Number of pages10
JournalEuropean Journal of Pediatrics
Volume183
Issue number9
Early online date1 Jun 2024
DOIs
Publication statusPublished - Sept 2024

Keywords

  • Newborn
  • Jaundice
  • Hyperbilirubinemia
  • Retinopathy of prematurity
  • Phototherapy
  • LATE-ONSET SEPSIS
  • TRANSCUTANEOUS BILIRUBIN
  • OXIDATIVE STRESS
  • NECROTIZING ENTEROCOLITIS
  • BILIVERDIN REDUCTASE
  • ANTIOXIDANT ACTIVITY
  • PRETERM
  • INFANTS
  • PHOTOTHERAPY
  • PROTECTION

Fingerprint

Dive into the research topics of 'Hyperbilirubinemia and retinopathy of prematurity: a retrospective cohort study'. Together they form a unique fingerprint.

Cite this